British Journal of Clinical Pharmacology · 1985 · 24 citations · 9 references
MedicinePharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyPharmacodynamicsBlood Pressure ControlBlood Pressure RegulationCardiovascular PharmacologyHypertension ControlHypertension ManagementHypertension PharmacotherapyAntihypertensive Drug TherapyAntihypertensive PharmacologyArterial Blood Pressure MeasurementBlood PressureHeart RateHypertensive Drug Response
We have completed a double-blind parallel group comparison of the 5-HT2 receptor antagonist ketanserin with placebo in 22 hypertensive patients. Ketanserin (20-40 mg twice daily) lowered sitting blood pressure more than placebo by 6.9 mm Hg systolic (NS), 13.1 mm Hg diastolic (P less than 0.05) and by 11.4 mm Hg mean arterial pressure (P less than 0.02). The fall in standing blood pressure was similar and we observed no first dose hypotensive effect. Ketanserin lowered the sitting heart rate by 11.1 beats/min (P less than 0.01). The drug was well tolerated.
9
Receptor binding profile of R 41 468, A novel antagonist at 5-HT2 receptors
J.E. Leysen, F. Awouters, Ludo Kennis et al. · Life Sciences · 1981 · 846 citations
Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.
G. J. Wenting, A J Man in 't Veld, A. J. J. Woittiez et al. · BMJ · 1982 · 90 citations · Full text
Mechanism of antihypertensive action of ketanserin in man.
I. W. Reimann, J C Frolich · BMJ · 1983 · 79 citations · Full text